Exozymes (EXOZ) Cash from Investing Activities (2023 - 2025)
Exozymes (EXOZ) posted quarterly Cash from Investing Activities of -$74990.0 for Q4 2025, up 64.36% year-over-year from -$45625.6 in Q4 2024, and down 463.5% quarter-over-quarter from -$13308.0 in Q3 2025.
Exozymes (EXOZ) Cash from Investing Activities (2023 - 2025) Analysis & Trends
Exozymes (EXOZ) has reported Cash from Investing Activities for 3 consecutive years, with -$74990.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Investing Activities rose 64.36% year-over-year to -$74990.0; the TTM figure through Dec 2025 stood at -$150218.0 (up 58.18% YoY), while the FY2025 annual figure was -$150218.0, up 58.18% from the prior year.
- Cash from Investing Activities slipped to -$74990.0 in Q4 2025 per EXOZ's latest filing, from -$13308.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $30857.0 in Q3 2024 and bottomed at -$210407.0 in Q4 2024.
- Historically, Cash from Investing Activities has averaged -$68797.4 across 3 years, with a median of -$37237.0 in 2024.
- On a YoY basis, Cash from Investing Activities climbed as much as 78.2% in 2025 and fell as far as 143.13% in 2025.
- Exozymes' Cash from Investing Activities stood at -$109743.0 in 2023, then tumbled by 91.73% to -$210407.0 in 2024, then soared by 64.36% to -$74990.0 in 2025.
- Business Quant data shows EXOZ's Cash from Investing Activities at -$74990.0 in Q4 2025, -$13308.0 in Q3 2025, and -$30874.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -74,990.00 |
| Dec 31, 2025 | -74,990.00 |
| Sep 30, 2025 | -13,308.00 |
| Sep 30, 2025 | -13,308.00 |
| Jun 30, 2025 | -30,874.00 |
| Jun 30, 2025 | -30,874.00 |
| Mar 31, 2025 | -31,046.00 |
| Mar 31, 2025 | -31,046.00 |
| Dec 31, 2024 | -210,407.00 |
| Dec 31, 2024 | -210,407.00 |
| Sep 30, 2024 | 30,857.00 |
| Sep 30, 2024 | 30,857.00 |
| Jun 30, 2024 | -37,237.00 |
| Jun 30, 2024 | -37,237.00 |
| Mar 31, 2024 | -142,429.00 |
| Mar 31, 2024 | -142,429.00 |
| Dec 31, 2023 | -109,743.00 |
| Dec 31, 2023 | -109,743.00 |